BMY:NYSEBristol-Myers Squibb Company Analysis

Bristol-Myers Squibb (BMY) is trading at $58.31, modestly above its 20‑day SMA (57.51) but just below the 50‑day SMA (58.43), indicating a neutral short‑term trend. The RSI sits at 53.6 and the MACD histogram is positive, offering a slight bullish tilt despite recent price weakness toward the $55.4 support level. Fundamentals remain solid: a PE of 16.3 is well below the industry average of 27.2, ROE is an impressive 38.7%, and the dividend yield of 4.32% positions BMY as a high‑yield defensive play, reflected in its recent ranking as a top defensive stock. Recent earnings beat and a new "Won't Lose" media campaign ahead of the FIFA World Cup 2026 add positive narrative, while the company carries a high debt‑to‑equity ratio (~231%) and a DCF‑derived fair value of $52.25, suggesting the current price carries a modest premium.